ATE374199T1 - N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form - Google Patents

N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form

Info

Publication number
ATE374199T1
ATE374199T1 AT03756734T AT03756734T ATE374199T1 AT E374199 T1 ATE374199 T1 AT E374199T1 AT 03756734 T AT03756734 T AT 03756734T AT 03756734 T AT03756734 T AT 03756734T AT E374199 T1 ATE374199 T1 AT E374199T1
Authority
AT
Austria
Prior art keywords
quinolyl
isoxazolyl
dimethoxy
phenylü
oxy
Prior art date
Application number
AT03756734T
Other languages
English (en)
Inventor
Naoki Matsunaga
Satoshi Yoshida
Ayako Yoshino
Tatsuo Nakajima
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32105192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE374199(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of ATE374199T1 publication Critical patent/ATE374199T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03756734T 2002-10-21 2003-10-21 N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form ATE374199T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002306101 2002-10-21

Publications (1)

Publication Number Publication Date
ATE374199T1 true ATE374199T1 (de) 2007-10-15

Family

ID=32105192

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03756734T ATE374199T1 (de) 2002-10-21 2003-10-21 N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form

Country Status (10)

Country Link
US (1) US7166722B2 (de)
EP (1) EP1559715B1 (de)
JP (1) JP3763414B2 (de)
AT (1) ATE374199T1 (de)
AU (1) AU2003301430A1 (de)
DE (1) DE60316590T2 (de)
DK (1) DK1559715T3 (de)
ES (1) ES2294317T3 (de)
PT (1) PT1559715E (de)
WO (1) WO2004035572A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384712B1 (de) * 1999-01-22 2007-03-07 Kirin Beer Kabushiki Kaisha Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität
JP4703183B2 (ja) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
KR101263032B1 (ko) * 2004-09-29 2013-05-09 바이엘 파마 악티엔게젤샤프트 4-｛4-［（｛［4-클로로-3-（트리플루오로메틸）페닐］아미노｝카르보닐）아미노］페녹시｝-ｎ-메틸피리딘-2-카르복사미드의 제조 방법
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US9037466B2 (en) * 2006-03-09 2015-05-19 Nuance Communications, Inc. Email administration for rendering email on a digital audio player
CA2758030C (en) 2009-01-16 2019-01-08 Exelixis, Inc. Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
EP2621481B2 (de) 2010-09-27 2022-10-19 Exelixis, Inc. Met- und vegf-doppelinhibitoren zur behandlung von kastrationsresistentem prostatakrebs und osteoblastischen knochenmetastasen
CA2826751C (en) 2011-02-10 2021-05-18 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
CN102532116B (zh) * 2011-08-09 2015-01-21 武汉迈德森医药科技有限公司 抗肿瘤靶向治疗药物tivozanib的合成方法
CN104072492A (zh) * 2013-11-27 2014-10-01 苏州摩尔医药有限公司 一种抗肿瘤靶向治疗药物Tivozanib的合成方法
DK3513809T3 (da) 2016-09-13 2022-05-02 Kyowa Kirin Co Ltd Medicinsk sammensætning, som omfatter tivozanib
MX2021005189A (es) 2018-11-05 2022-01-18 Aveo Pharmaceuticals Inc Uso de tivozanib para tratar sujetos con cancer refractario.
WO2023096651A1 (en) 2021-11-26 2023-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating bile duct cancers with tivozanib
CN114213404B (zh) * 2021-12-27 2024-08-06 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
WO2024095127A1 (en) 2022-10-31 2024-05-10 Pliva Hrvatska D.O.O. Solid state forms of tivozanib and process for preparation thereof
WO2024110606A1 (en) 2022-11-25 2024-05-30 Synthon B.V. A process for preparation of cabozantinib or tivozanib
CN117327061A (zh) * 2023-09-12 2024-01-02 武汉迈德森医药科技股份有限公司 一种替沃扎尼盐酸盐的制备方法及相关物质
CN117417336A (zh) * 2023-10-19 2024-01-19 武汉迈德森医药科技股份有限公司 一种替沃扎尼对甲苯磺酸盐的晶型及其制备方法和应用
WO2025120654A1 (en) * 2023-12-05 2025-06-12 Natco Pharma Limited An improved process for the preparation of tivozanib hydrochloride hydrate
WO2025220660A1 (ja) * 2024-04-15 2025-10-23 協和キリン株式会社 チボザニブ原薬およびその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1047418T3 (da) * 1997-12-22 2005-11-21 Bayer Pharmaceuticals Corp Inhibering af raf-kinase ved hjælp af substituerede heterocykliske urinstoffer
HK1049839A1 (en) * 1999-12-24 2003-05-30 Kirin Pharma Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
EP1506962B1 (de) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Stickstoff enthaltende aromatische Heterozyklen
EP1382604B1 (de) * 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Chinolinderivate mit einer azolylgruppe und chinazolinderivate
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤

Also Published As

Publication number Publication date
DE60316590D1 (en) 2007-11-08
EP1559715B1 (de) 2007-09-26
WO2004035572A1 (ja) 2004-04-29
DE60316590T2 (de) 2008-06-19
US7166722B2 (en) 2007-01-23
ES2294317T3 (es) 2008-04-01
US20060052415A1 (en) 2006-03-09
JPWO2004035572A1 (ja) 2006-02-16
EP1559715A1 (de) 2005-08-03
EP1559715A4 (de) 2006-03-29
DK1559715T3 (da) 2007-12-27
PT1559715E (pt) 2007-10-24
AU2003301430A1 (en) 2004-05-04
JP3763414B2 (ja) 2006-04-05

Similar Documents

Publication Publication Date Title
ATE374199T1 (de) N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
SE0102300D0 (sv) Compounds
HU9600834D0 (en) Quinazoline derivatives
CY1110631T1 (el) Διαλυτοποιημενα δηλητηρια τοποϊσομερασης
MY146279A (en) Compounds affecting glucokinase
CY1112571T1 (el) 2,4-πυριμιδινοδιαμινες χρησιμες στην αντιμετωπιση νεοπλασματικων νοσων, φλεγμονωδων διαταραχων και διαταραχων του ανοσοποιητικου συστηματος
DE60215814D1 (de) Vinylphenyl-derivate als glk-aktivatoren
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
CY1108295T1 (el) Παραγωγα μονοσακχαριτη αβερμεκτινης τα οποια εχουν παρασιτοκτονες ιδιοτητες
CY1111851T1 (el) Αρωματικες ενωσεις ως αντι-φλεγμονωδεις, ανοσορυθμιστικοι και αντι-πολλαπλασιαστικοι παραγοντες
BR0113590A (pt) 7-oxo-piridopirimidinas
DK1251846T3 (da) C4-Carbonattaxaner
ATE137501T1 (de) Benzazin-verbindungen und deren pharmazeutische verwendungen
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
NO20023486L (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
ATE137223T1 (de) Leukotrien-b4-antagonisten
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
ES2089974B1 (es) Utilizacion de los derivados de 1-(4-)4-aril (o heteroaril)-1-piperazinil)-butil)-1-h-azol para la preparacion de medicamentos destinados al tratamiento de los trastornos de la secrecion gastrica.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
RU2008127260A (ru) Производные хиназолинона в качестве антагонистов ваниллоидов
ATE139523T1 (de) Neue verbindungen und deren medizinale verwendung
RU2004112422A (ru) Роувастатин в преддеменционных состояниях
EP1428825A4 (de) Benzimidazolderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties